Back to News
Market Impact: 0.2
XORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A Year
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
XORTX Therapeutics plans to submit an Investigational New Drug application to the U.S. FDA in Q4 2026 for its late-stage gout and kidney-disease programs. The planned regulatory filing marks a positive development milestone, though the long timeline and absence of clinical data limit near-term valuation impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
XRTX0.35
More News
- California’s Bay Area debates data centres ahead of US midterm elections
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- ‘Going hungry’: Garment workers in Bangladesh say wages barely cover needs
- How Trump’s trade policy is handing Asia to Beijing
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy